C4 Therapeutics Operating Expenses Growth & History (CCCC)
C4 Therapeutics's operating expenses was $151.2M for fiscal 2025.
View full C4 Therapeutics company overviewC4 Therapeutics annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $151.2M | −$4.0M | −2.60% |
| 2024 | 2024-12-31 | $155.2M | −$4.6M | −2.87% |
| 2023 | 2023-12-31 | $159.8M | −$843,000 | −0.52% |
| 2022 | 2022-12-31 | $160.6M | $32.7M | +25.57% |
| 2021 | 2021-12-31 | $127.9M | $34.3M | +36.60% |
| 2020 | 2020-12-31 | $93.6M | $36.8M | +64.77% |
| 2019 | 2019-12-31 | $56.8M | — | — |
C4 Therapeutics quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $33.1M | −$1.9M | −5.43% |
| Q1 2026 | 2026-03-31 | $33.9M | −$2.5M | −6.77% |
| Q4 2025 | 2025-12-31 | $34.2M | −$8.7M | −20.34% |
| Q3 2025 | 2025-09-30 | $45.6M | $2.0M | +4.67% |
| Q2 2025 | 2025-06-30 | $35.0M | $1.5M | +4.53% |
| Q1 2025 | 2025-03-31 | $36.4M | $1.1M | +3.24% |
| Q4 2024 | 2024-12-31 | $42.9M | $2.2M | +5.40% |
| Q3 2024 | 2024-09-30 | $43.6M | $4.7M | +12.16% |
| Q2 2024 | 2024-06-30 | $33.4M | −$6.8M | −16.86% |
| Q1 2024 | 2024-03-31 | $35.3M | −$4.7M | −11.83% |
| Q4 2023 | 2023-12-31 | $40.7M | −$459,000 | −1.12% |
| Q3 2023 | 2023-09-30 | $38.9M | −$362,000 | −0.92% |
| Q2 2023 | 2023-06-30 | $40.2M | −$986,000 | −2.39% |
| Q1 2023 | 2023-03-31 | $40.0M | $964,000 | +2.47% |
| Q4 2022 | 2022-12-31 | $41.1M | $5.8M | +16.45% |
| Q3 2022 | 2022-09-30 | $39.2M | $6.5M | +19.81% |
| Q2 2022 | 2022-06-30 | $41.2M | $9.3M | +29.22% |
| Q1 2022 | 2022-03-31 | $39.0M | $11.1M | +39.69% |
| Q4 2021 | 2021-12-31 | $35.3M | $8.2M | +30.07% |
| Q3 2021 | 2021-09-30 | $32.8M | $6.0M | +22.23% |
| Q2 2021 | 2021-06-30 | $31.9M | $11.4M | +55.38% |
| Q1 2021 | 2021-03-31 | $27.9M | $8.8M | +45.84% |
| Q4 2020 | 2020-12-31 | $27.2M | — | — |
| Q3 2020 | 2020-09-30 | $26.8M | $11.4M | +74.40% |
| Q2 2020 | 2020-06-30 | $20.5M | — | — |
| Q1 2020 | 2020-03-31 | $19.2M | — | — |
| Q3 2019 | 2019-09-30 | $15.4M | — | — |
C4 Therapeutics operating expenses trends
Over the last five fiscal years, C4 Therapeutics's operating expenses increased from $93.6M to $151.2M, a change of $57.5M. The latest reported quarter, Q2 2026, shows $33.1M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review C4 Therapeutics source filings ↗